Exact Sciences (EXAS) Competitors $52.70 -1.22 (-2.26%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EXAS vs. MEDP, CRL, PRAH, ALNY, BIIB, UTHR, INCY, NBIX, BMRN, and EXELShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Medpace (MEDP), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "medical" sector. Exact Sciences vs. Medpace Charles River Laboratories International PRA Health Sciences Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Medpace (NASDAQ:MEDP) and Exact Sciences (NASDAQ:EXAS) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability. Does the MarketBeat Community prefer MEDP or EXAS? Exact Sciences received 623 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 72.92% of users gave Exact Sciences an outperform vote while only 63.77% of users gave Medpace an outperform vote. CompanyUnderperformOutperformMedpaceOutperform Votes35263.77% Underperform Votes20036.23% Exact SciencesOutperform Votes97572.92% Underperform Votes36227.08% Do institutionals & insiders have more ownership in MEDP or EXAS? 78.0% of Medpace shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 20.3% of Medpace shares are held by company insiders. Comparatively, 1.4% of Exact Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is MEDP or EXAS more profitable? Medpace has a net margin of 17.66% compared to Exact Sciences' net margin of -7.95%. Medpace's return on equity of 50.87% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Medpace17.66% 50.87% 19.61% Exact Sciences -7.95%-6.17%-2.98% Do analysts rate MEDP or EXAS? Medpace presently has a consensus price target of $380.00, suggesting a potential upside of 16.53%. Exact Sciences has a consensus price target of $74.47, suggesting a potential upside of 41.31%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Exact Sciences is more favorable than Medpace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 0 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.45Exact Sciences 0 Sell rating(s) 1 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.95 Which has more volatility and risk, MEDP or EXAS? Medpace has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Does the media prefer MEDP or EXAS? In the previous week, Exact Sciences had 3 more articles in the media than Medpace. MarketBeat recorded 12 mentions for Exact Sciences and 9 mentions for Medpace. Exact Sciences' average media sentiment score of 1.07 beat Medpace's score of 0.44 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exact Sciences 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, MEDP or EXAS? Medpace has higher earnings, but lower revenue than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedpace$1.89B5.37$282.81M$11.4228.55Exact Sciences$2.50B3.90-$204.15M-$1.17-45.04 SummaryMedpace and Exact Sciences tied by winning 9 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.98B$3.06B$5.07B$8.89BDividend YieldN/A11.18%4.99%4.07%P/E Ratio-45.048.5183.5712.93Price / Sales3.90215.991,220.3088.33Price / Cash3,166.05406.7839.4636.25Price / Book3.043.316.936.25Net Income-$204.15M-$32.86M$119.12M$225.93M7 Day Performance3.48%0.56%-1.83%-1.32%1 Month Performance-24.15%-0.22%-3.64%0.60%1 Year Performance-19.10%26.01%31.64%26.23% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.8868 of 5 stars$52.70-2.3%$74.47+41.3%-21.7%$9.98B$2.50B-45.046,600Positive NewsMEDPMedpace4.7711 of 5 stars$326.09+3.5%$380.00+16.5%+18.2%$9.79B$1.89B28.555,900CRLCharles River Laboratories International4.8024 of 5 stars$187.90+1.0%$214.38+14.1%-1.4%$9.52B$4.13B23.5221,800Analyst DowngradePRAHPRA Health SciencesN/A$165.21flatN/A+0.0%$10.70B$3.18B42.3618,100Analyst ForecastALNYAlnylam Pharmaceuticals4.3868 of 5 stars$248.79+6.2%$298.09+19.8%+50.5%$30.22B$1.83B0.002,100Analyst ForecastBIIBBiogen4.8601 of 5 stars$156.00+0.4%$258.96+66.0%-32.2%$22.65B$9.84B14.097,570Analyst DowngradeUTHRUnited Therapeutics4.5219 of 5 stars$364.33+1.0%$370.86+1.8%+59.1%$16.10B$2.33B16.001,168Analyst RevisionPositive NewsINCYIncyte3.9 of 5 stars$71.05+0.7%$77.16+8.6%+29.9%$13.59B$3.70B507.542,524Analyst ForecastNBIXNeurocrine Biosciences4.9503 of 5 stars$123.29+3.5%$163.91+32.9%+12.7%$12.06B$1.89B33.051,400Positive NewsBMRNBioMarin Pharmaceutical4.9885 of 5 stars$62.56+1.0%$94.20+50.6%-28.5%$11.81B$2.42B37.463,401Analyst RevisionEXELExelixis4.7763 of 5 stars$34.65+0.7%$31.44-9.3%+65.6%$9.83B$1.83B22.211,310Insider Trade Related Companies and Tools Related Companies Medpace Alternatives Charles River Laboratories International Alternatives PRA Health Sciences Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EXAS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
